| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
NRXP sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| COO | 100.0K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 17, 2024 | Javitt Jonathan C62 | Chairman And Chief Scientist | Buy | 40,000 | $1.17 | $46,800.00 | +89.6% | +25.0% | +39.0% | |
| Aug 30, 2023 | Hurvitz Chaim | Director | Buy | 70,000 | $0.29 | $20,125.00 | +14.0% | +4.9% | -42.3% | |
| Aug 30, 2023 | Gorovitz Aaron | Director | Buy | 35,000 | $0.32 | $11,196.50 | +50.0% | +4.9% | -42.3% | |
| Aug 23, 2023 | Javitt Jonathan C62 | Chief Scientist | Buy | 100,000 | $0.33 | $33,000.00 | +28.9% | +3.7% | -28.0% | |
| Aug 22, 2023 | Javitt Jonathan C62 | Chief Scientist | Buy | 200,000 | $0.32 | $64,400.00 | +136.7% | +3.2% | -37.0% | |
| Dec 16, 2022 | Van Voorhees Seth | Chief Financial Officer | Buy | 30,000 | $1.10 | $33,000.00 | +183.6% | -40.2% | -70.5% | |
| Dec 16, 2022 | Willard Stephen H | Chief Executive Officer | Buy | 50,000 | $1.17 | $58,500.00 | New | -40.2% | -70.5% | |
| Dec 7, 2022 | Javitt Jonathan C62 | Director, 10% Owner | Sell | 400,000 | $1.00 | $400,000.00 | -3.0% | -50.0% | -77.1% | |
| Nov 30, 2022 | Javitt Daniel C.75 | 10% Owner | Sell | 22,171 | $1.50 | $33,351.62 | -0.2% | -29.2% | -76.1% | |
| Nov 28, 2022 | Flynn Patrick John | Director | Buy | 11,750 | $1.25 | $14,662.50 | -117.5% | -19.2% | -73.4% |